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Abstract
The global increase in the incidence of obesity has emerged as one of the most serious public health risks in
recent years. Despite the enormity of the obesity pandemic, there are currently only two FDA-approved therapies for
its treatment and these drugs exhibit modest efficacy and have limiting side effects. Prieurianin is a plant limonoid
product that deters feeding in insect larvae. We investigated in this study the effects of prieurianin on weight loss and
adipogenesis. Our results showed that prieurianin causes weight loss by reducing energy intake in obese mice on highcalorie diet. We also found that prieurianin is anti-adipogenic in cultured preadipocytes and adipocytes by inhibiting
proliferation and differentiation of preadipocytes into adipocytes, and induces either dedifferentiation or delipidation
of mature adipocytes. Whether prieurianin can potentially be used for obesity treatment in human warrants further
investigation.

Keywords: Prieurianin; Obesity; Appetite; Adipogenesis; Weight
loss; Tolerance; Preadipocytes; Adipocytes

it is imperative to identify new drugs to address the unmet needs
for the treatment of obesity.

Introduction

Some compounds in plants have been developed for their use
in insect pest management without harming the environment
[13]. Prieurianin, a limonoid isolated from several plant species,
exhibits specific anti-feedant activity in insect using a diet choice
bioassay [14]. The drug has no apparent effects on the efficiency
of conversion of ingested food in larvae and seems to antagonize
20-hydroxyecdysone activity in Drosophila cells [14, 15].

The completion of some recent late stage anti-obesity clinical
trials using combinations of various repositioned drugs including
anticonvulsant, antidepressant and a controlled substance of
the amphetamine class, seemed to meet FDA criteria for clinical
efficacy [12]. Other than the novel monotherapeutic lorcaserin,
these repositioned drugs, however, all have a history of safety
issues. The potential side effects associated with the long-term use
of these agents remain to be evaluated. Despite these progresses,

Materials and Methods
Animals, diets, drugs, and reagents
All animal procedures were approved by the Institutional
Animal Care and Use Committee. For all in vivo efficacy studies,
prieurianin was dissolved in DMSO and then given intraperitoneally
as a mixture in 10% Cremophor EL (Sigma-Aldrich, St. Louis, MO) [16]
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In light of its ability to deter feeding in insects, we hypothesized
that prieurianin would interfere with feeding behaviour in mice
and cause weight loss. In this report, we showed that prieurianin
suppresses appetite and causes weight loss in diet-induced obese
mice and inhibits adipogenesis in cell culture model of preadipocytes.
Our results suggest that prieurianin may be an effective anti-obesity
drug candidate and also serve as a pharmacological tool for probing
the biology of adipose tissue.
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The alarming rise in the incidence of obesity worldwide has emerged
as one of the most pressing public health issu es in recent years [1].
The obesity pandemic is thought to be associated with a sedentary
lifestyle and the overconsumption of energy-rich food. It is clear that
obesity raises the incidence of some co-morbid health risks such
as diabetes, hypertension, cardiovascular and metabolic diseases
[2]. Despite the enormity of the obesity pandemic and the wealth
of information that has been gained in the past decade about the
hormonal and transcriptional mechanisms that regulate energy
metabolism, there are only two drugs currently approved by the FDA
for the treatment of obesity.These include orlistat that blocks the
absorption of dietary fat [3], and sibutramine, a specific reuptake
inhibitor for norepinephrine and serotonin that acts in the central
nervous system (CNS) to reduce energy intake [4]. These drugs have
limited efficacies and side effects are commonly reported [5], which
are further confounded by diminishing response in the long-term
treatment of obesity [6,7]. The loss of efficacy, which may be a result
of drug induced tolerance, not only occurs with the first generation
appetite suppressant but are observed with the other classes of
drug candidates as well including rimonabant [8], leptin [9], and
melanotan II [10].
Moreover, anti-obesity drug development
strategy continues to focus on either central or peripheral acting
inhibitors of food intake [11], which will likely encounter similar
problems [6]. Recent suspension of sibutramine in Europe, and the
FDA-issued warning of heart risk in patients taking sibutramine
further limit the pharmacotherapeutic option for obesity.
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days and then replenished in the propagation medium as above.
Nile Red (Sigma, St. Louis, MO) staining following differentiation
was performed as described by adding a 1 mg ml -1 stock solution
to cultured cells to a final concentration of 5 g ml-1 and then
visualized under fluorescence microscope [19], and compared to
preadipocytes differentiated in the presence of prieurianin. To
determine the effect of prieurianin on dedifferentiation/lipolysis,
preadipocytes were differentiated into adipocytes as above and
further cultured for 5-6 days, and then treated with or without drug
for an additional 5-6 days before Nile Red staining.

to the animals, and vehicle-treated controls received equivolume
injections of 0.5% of DMSO in Cremophor. For diet-induced obesity
studies, 12-14 week-old normal C57BL/6 (B6) mice (The Jackson
Laboratory, Bar Harbor, ME) were acclimatized for at least one week
on a 12-hour light/dark cycle at 68-72oF and then fed a high-fat
diet containing 45 kcal% fat (Research Diets, Inc., New Brunswick,
NJ), until their mean body weight reached approximately 30 g, and
remained on the high-fat diet for the duration of the study. Mice had
access to the high fat diet ad libitum during treatment in all studies.
Blood glucose and insulin levels were measured and adipose tissues
were harvested for weighing at the end of the experiments. Food
intake and body weight were measured every two days for the
duration of the study. Mice were euthanized by CO2 asphyxiation
according to the Association for Assessment and Accreditation of
Laboratory Animal Care International guidelines. All studies were
performed with at least 10 to 20 animals per group.

Annexin V assay
The Guava Nexin assay measures membrane changes associated
with apoptosis using Annexin V-PE, and 7-aminoactinomycin D
(7-AAD) to identify dead cells, and experiments were conducted
according to manufacturer’s specification (Millipore, Billerica, MA).
In brief, preadipocytes in culture were treated with prieurianin
for 24 hours and then resuspended in 1X Nexin buffer solution,
supplemented with 5 l of Annexin-V solution and 5 l of 7-AAD.
To ensure the binding of the label, samples were incubated on ice.
Finally, the 1X Nexin buffer was added and samples were analyzed
in the Guava cytometer.

Prieurianin was obtained from MicroSource Discovery Systems
(Gaylordsville, CT), and sibutramine from Sigma-Aldrich (St. Louis,
MO). Tumor necrosis factor  was cloned into the pGEX-6P-1 vector
(GE Healthcare, Piscataway, NJ) as a fusion protein with glutathione
Stransferase and produced from E. coli following IPTG induction and
purification as described according to manufacturer’s specification.

Glucose, insulin and adipose tissues

Cell culture and adipocyte differentiation

Fed glucose and insulin levels were measured from blood
samples taken at the end of the treatment period. Glucose was
measured using Cardio Chek meter (PTS, Indianapolis, IN). Insulin
levels were measured in plasma using an ELISA kit (Crystal Chem
Inc., Downers Grove, IL). Necropsy analysis was performed for two
fat depots, subcutaneous and visceral fat, by weighing the dissected
tissues.

NIH-3T3/L1 (L1) (American Type Culture Collection,
Manassas, VA) and OP9 stromal (a gift of Dr. Perry Bickel,
University of Texas Health Science Center, Houston, TX)
cells were cultured at 37°C with 10% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% (v/v) fetal calf serum (Invitrogen), 1
mM sodium pyruvate, 0.1 mM non-essential amino acids, 2
mM L-glutamine, 100 g ml-1 streptomycin sulfate, and 100
U ml-1 penicillin. To assess preadipocytes proliferation, cells
were plated in 12 well dishes and then treated with various
concentrations of prieurianin. Cell growth was measured daily on
a Coulter cell counter. To differentiate L1 cells into adipocytes,
cells were incubated with 250 nM dexamethasone, 450 M
3-isobutyl-1-methylxanthine, and 167 nM insulin for 2 days, followed
by 167 nM insulin for an additional 3 days as described (17). For OP9
cells (18), differentiation was initiated with a serum replacement
medium composed of MEM-a with 15% KnockOut SR (Invitrogen,),
100 g ml1 streptomycin sulfate, and 100 U ml-1 penicillin, for 2

Statistical analyses were performed using commercially
available software package (PRISM, GraphPad Software, Inc., La
Jolla, CA) or the data analysis add-in for Microsoft Excel. Either
single factor ANOVA or Student’s t-tests were used for all analysis
as indicated. P values of less than 0.05 were considered statistically
significant.

Results
Anorexigenicity. The observation that prieurianin (Figure1A)
is a feeding deterrent in insect larvae that presumably acts by
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Figure 1: Prieurianin in mouse model of diet-induced obesity (DIO). A, Structure of prieurianin. B, C, Body weight and amount of food consumed by DIO B6 mice that
were given either 1 or 3 mg kg-1 of prieurianin for three weeks. Prieurianin causes weight loss (B) and reduced food consumption (C) in DIO B6 mice compared
to untreated and vehicle-treated controls. All studies consisted of ten mice per group. Statistics were conducted as an ANOVA; asterisk, P<0.05 versus untreated and
vehicle-treated controls. Error bars indicate s.e.m.
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Figure 2: Effects of drug holiday schedule for prieurianin in DIO mice. A, B,
Drug holiday treatment protocols for prieurianin in DIO mice. This on-off
or cyclical treatment strategy comprised of specified doses of prieurianin at
either 3 or 5 mg kg-1 were given as indicated for a defined duration coupled
with intermittent drug holiday to overcome drug-induced tolerance. C,
D, Drug holiday treatment schedule with either 3 or 5 mg kg-1 prieurianin
circumvented drug-induced tolerance and produced a sustained weight loss
(C) and reduced food intake (D). All studies consisted of 10 animals per
group, except for the 3 and 5 mg kg-1 prieurianin treated groups (n=20).

antagonizing 20-hydroxyecdysone in Drosophila cells prompted
us to ask whether the anti-feedant effects of prieurianin can be
exploited for the treatment of obesity. To test this hypothesis,
we examined the effects of prieurianin on weight loss in the dietinduced obese (DIO) C57BL/6 (B6) mice, since this model has been
widely used to investigate the underlying mechanisms of obesity in
human [20, 21]. DIO B6 mice were given high fat diet for 15 weeks and
then prieurianin was administered intraperitoneally (i.p.) daily with
either 1 or 3 mg kg-1 prieurianin for three weeks. Prieurianin caused
a dose-dependent weight loss (Figure1B) that was accompanied by
70-80% decrease in food consumption, which eventually returned
to normal levels by the end of the treatment period (Figure 1C).
Notably, a gradual regain in body weight was observed following
the first week of treatment (Figure1B), suggesting the onset of druginduced tolerance.
One of the major unresolved problems in the pharmacotherapy of
obesity is the diminishing efficacy of drugs with chronic treatment
[6]. To assess whether drug-induced tolerance can be circumvented
by “drug holidays”, mice were treated with either 3 or 5 mg kg-1
prieurianin for 5 or 3 days, respectively, followed by 5 days of drug
withdrawal, and repeating this regimen for 4 cycles (Figure 2A and
B). DIO B6 mice from the experiments in (Figure1) were maintained
on the high calorie diet for four additional weeks without treatment
and then subjected to the drug holiday treatment cycle. This
treatment protocol, at either 3 or 5 mg kg-1 prieurianin, produced
a greater response than daily treatment, with up to 20% weight
loss at either dosage, and no observable weight regain at the end
of the treatment cycle (Figure 2C). Food consumption decreased
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Figure 3: Effects of prieurianin on plasma glucose and insulin, and adipose
mass in DIO mice. Plasma glucose (A) and insulin (B) levels were measured
at the end of prieurianin treatment. Prieurianin treatment decreased plasma
glucose (filled bar) and insulin (opened bar) levels in DIO mice. C, D,
Significant reduction in adipose mass was observed in post-mortem analysis
of in subcutaneous (C) and visceral (D) compartments of prieurianin treated
DIO B6 mice compared to untreated and vehicle (DMSO)-treated controls.
All studies consisted of 10 animals per group, except for the 3 and 5 mg kg-1
treated groups (n=20) in A and B. Experiments were conducted in triplicates
for C and D selected randomly from the animals. Statistics were conducted
as an ANOVA; asterisk, P<0.05 versus untreated and vehicle-treated controls.
Error bars indicate s.e.m.

precipitously initially, but gradually returned to approximately 6070% of normal feeding and maintained at that level for the duration
of the treatment cycle (Figure 2D). Fed glucose and insulin levels
also showed a trend of decrease at the end of treatment period
(Figure 3A and B).

Anti-adipogenesis
Post-mortem analysis showed >50% decrease in subcutaneous
and visceral fat depots in prieurianin-treated DIO B6 mice (Figure
3C and D), compared to untreated and vehicle-treated controls. The
ability of prieurianin to reduce fat mass led us to determine the
effects of prieurianin on the differentiation of cultured preadipocytes
into mature adipocytes using either the L1 preadipocytes
[17], or the OP9 mouse stromal cells [18] that are capable of
differentiating into adipocytes. Prieurianin inhibited the proliferation
of L1 preadipocytes in a dose-dependent manner (Figure 4A), as
well as their post-confluent mitosis and clonal expansion, evident
from the reduced 3[H]thymidine uptake following differentiation
induction (Figure 4B). Prieurianin also inhibited the differentiation
of OP9 stromal cells into adipocytes as evident from the reduced
Oil Red O stained lipid-accumulating adipocytes relative to the
untreated/undifferentiated and the differentiated controls (Figure
5A). The positive control, TNF  [22,23], also inhibited OP9 cells
differentiation (Figure 5A). These effects of prieurianin were
recapitulated in the L1 preadipocytes (data not shown). The decrease
in adipocytes was not a result of prieurianin-induced apoptosis, as
indicated by the lack of annexin V binding to phosphatidylserine,
in contrast to stromal cells treated with doxorubicin, a cytotoxic
drug that causes apoptosis (Figure 4C). Similarly, apoptosis was not
observed in prieurianin-treated L1 preadipocytes (data not shown).
Volume 1• Issue 1•1000101

CS

lishing
Pub
G

r
p
ou

J Diabetes Metab
ISSN:2155-6156 JDM an open access journal

2

U

20

3

0
m
g

30

0
30

0

4

OM
I

30

*

1

5

35

3mg/kg
5mg/kg

nt

x
40 x x x x x x x x x x x x x x x x x x

Untreated
Vehicle

40

2

-1

50

3mg/kg
5mg/kg

3

U

45

Untreated
x Vehicle

Food Intake, g

Body Weight, g

50

4

re
at
ed
Ve
hi
cl
e
3
m
g
kg

D

C

D

Subcutaneous fat (g)

Prieurianin was given daily intraperitoneally at a dose of 3mg/Kg for 5 days
Treatment was repeated every 10 days for 4 cycles

Citation: Kablan A, Saunders RA, Szkudlarek-Mikho M, Chin JB, Bosio RM, et al. (2010) Prieurianin Causes Weight Loss in Diet-Induced Obese Mice
and Inhibits Adipogenesis in Cultured Preadipocytes. J Diabetes Metab 1:101. doi:10.4172/2155-6156.1000101

Page 4 of 5

10
0

4

5

6

7

2,500
2,000
1,500
1,000
500
0

* * *

Days

Vehicle

TNF

Prieurianin

B

0

0.25 0.5

1

2

Prieurianin, M

L1 Adipocytec

20

H-Thymidine Uptake (CPM)

Control
Vehicle
0.5M
1M
2M

3

Cell Nymber (x103)

30

Untreated

Op9 Stromal Cells

A

B

A

C
Vehicle

Prieurianin

Doxorubicin

Figure 4: Effects of prieurianin on L1 preadipocytes and OP9 stromal
cells. ( A), L1 preadipocytes were cultured in 12-well dishes and counted
daily using a Coulter cell counter. Prieurianin inhibits L1 preadipocytes
proliferation. (B), L1 preadipocytes were cultured to confluence and then
placed in a differentiation cocktail for 48 hours followed by 3H-thymidine uptake
and cell lysates were subjected to scintillation counting. Prieurianin inhibits
the postconfluent mitosis and clonal expansion of L1 preadipocytes. (C),
Prieurianin does not cause apoptosis in OP9 cells as measured by annexin
V binding to cell surface phosphatidylserine, compared to the cytotoxic drug,
doxorubicin. Studies were performed in triplicates. Asterisk, P<0.05 versus
untreated controls. Error bars indicate s.e.m.

To assess the effects of prieurianin in mature adipocytes, L1
preadipocytes were differentiated into adipocytes followed by
treatment with either TNF  or prieurianin. Consistent with previous
report [22], TNF  induced rapid lipolysis, resulting in significant
loss of Nile Red stained adipocytes (Figure 5B). Though less potent,
prieurianin also caused a loss of lipid in the adipocytes, marked by
reduced Nile Red positive cells compared to differentiated control
and vehicle-treated cells (Figure 5B).

Discussion
Despite
a
growing
obese
population
worldwide,
pharmacotherapy for obesity is limited as there are currently only
two FDA-approved drugs for its treatment in U.S. Recent FDA issued
heart risk warning in U.S. for sibutramine and its withdrawal in
Europe, as well as new concerns for potential liver toxicity with
orlistat, further reduced the armamentarium for the combat of
obesity. Moreover, the use of repositioned drugs comprising
of combinatorial mixture of anticonvulsant, antidepressant, or
psychoactive stimulant, also poses questions of unknown longterm
safety concerns, as these drugs all have various known risks and
side effects [24]. These issues all point to an urgent need for the
development of more efficacious and safe pharmacotherapeutics
for obesity.
Our studies here showed that prieurianin, a plant-derived
limonoid product, which exhibits feeding deterrent activity in
insect larvae, has biological activity in high-fat diet induced
obese mice that results in appetite suppression, leading to
decreased energy intake in mice and weight loss. Further,
prieurianin also inhibits the proliferation and differentiation
of preadipocytes, as well as causing mature adipocytes to lose
their lipid content. These findings suggest a novel anti-obesity
drug candidate characterized by a dual anorexigenic and anti-

adipogenic property that is distinct from currently available
pharmaceutical therapies and pipeline products in development
that focused on either suppressing satiety or inhibiting energy
homeostasis [11]. The anorexigenic effect of prieurianin could not
have been due to taste aversion because the drug was delivered
by IP injection into the mice. Moreover, the diet choice bioassay
in insect larvae also suggests a specific effect of prieurianin
on feeding stimulus [14]. Although it was shown to antagonize
20-hydroxyecdysone action in Drosophila cells [15], the precise
mechanism of action of prieurianin, however, is unknown with
respect to its effects on appetite suppression in mice and
its inhibition of adipogenesis in cultured preadipocytes. It
is noteworthy that prieurianin was recently shown to inhibit
endocytosis and also block brassinosteroid-induced gene expression
in germinating seedlings of Arabidopsis thaliana [25]. It is unclear
how prieurianin-inhibited endocytosis translates into its antiobesity effects. Furthermore, the inhibition of hormone-induced
transcription in germinating seedlings by prieurianin suggests that
the drug may have similar effects on the transcriptional regulation
of adipogenesis in preadipocytes by disrupting gene expression
program during differentiation. Hence, identifying the molecular
target(s) of prieurianin might yield insights into its anorexigenic
activity in suppressing energy intake and its anti-adipogenic
potential in the development of adipose tissue.
Long-term efficacy and effectiveness of obesity treatments
are known to have poor outcome [26]. The potential of druginduced tolerance associated with anti-obesity therapeutics is long
recognized, but circumventing its development has not been fully
addressed [6]. Our studies here demonstrated that drug-induced
tolerance resulting from chronic pharmacotherapy for obesity
could be overcome by a cyclical drug holiday treatment strategy,
which produces a greater and more durable therapeutic response
as evident by the sustained weight loss and reduced energy intake.
Hence, the on-off treatment protocol may potentially restore the
efficacy of currently available anti-obesity drugs as well as other
experimental pharmacotherapeutics that are prone to drug-induced
tolerance in the long-term treatment of obesity. Besides, decreasing
the frequency of drug exposure using the drug holiday treatment
protocol may reduce the incidence and disposition to the toxicities
of these anti-obesity drugs.
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Figure 5: Prieurianin inhibits adipogenesis. (A), Prieurianin inhibits the
differentiation of OP9 cells into adipocytes, stained with Oil Red O. TNFα,
a cytokine and potent inhibitor of differentiation, is used as control. (B),
Prieurianin causes either dedifferentiation or delipidation of differentiated
adipocytes, stained with Nile Red, compared to untreated and vehicletreated adipocytes. TNF, which causes lipolysis, serves as control. All
experiments were performed for at least three or more times and representative
micrographs of the experiments were shown.
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Taken together, the findings in this study showed that prieurianin
is a novel anti-obesity therapeutic candidate that exhibits a dual
anorexigenic and anti-adipogenic property. Therefore, investigating
the precise molecular target of prieurianin, and characterizing
its long-term efficacy and toxicology profile will determine its
suitability for further development as a pharmacotherapeutic for
obesity.

12. Jones D (2009) Novel pharmacotherapies for obesity poised to enter market.
Nat Rev Drug Discov 8: 833- 834 .
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